24 recruiting, 5 completed, 5 not yet recruiting, 3 active not recruiting. 29 Phase 2, 8 Phase 3, 7 Phase 1.
Follow Summit Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) Ivonescimab, IP PTX - Phase II, Ivonescimab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2027-01-16 | 2026-08-27 |
| Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets Ivonescimab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 158 | 2026-11-01 | 2026-06-04 |
| A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab - Renal Cell Carcinoma, Clear Cell | Phase 2 | Not yet recruiting | Summit Therapeutics | 100 | 2026-10-19 | 2026-10-16 |
| A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma Ivonescimab Dose 1, enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC) | Phase 2 / Phase 3 | Recruiting | Summit Therapeutics | 800 | 2026-09-10 | 2026-09-11 |
| Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases Ivonescimab, Bevacizumab, FOLFIRI Protocol - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | UNICANCER | 130 | 2026-08-31 | 2026-05-19 |
| A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer Tepotinib, Ivonescimab - Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-05-27 | 2026-09-16 |
| Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN Ivonescimab 10 mg/kg, Ligufalimab, Pembrolizumab (KEYTRUDA ®) - Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 3 | Recruiting | Groupe Oncologie Radiotherapie Tete et Cou | 780 | 2026-05-05 | 2026-05-20 |
| Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC Ivonescimab, carboplatin, pemetrexed - Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC) | Phase 2 | Recruiting | Massachusetts General Hospital | 46 | 2026-05-01 | 2026-07-15 |
| A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer Ivonescimab, Stereotactic Radiosurgery - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 53 | 2026-04-10 | 2026-04-17 |
| A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer Ivonescimab, Dato-DXd, Osimertinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 66 | 2026-04-09 | 2026-07-13 |
| A Study of Ivonescimab in People With Leiomyosarcoma Ivonescimab - Leiomyosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2026-04-01 | 2026-10-22 |
| Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg - Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | PrECOG, LLC. | 60 | 2026-03-30 | 2026-08-28 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma Ivonescimab, FOLFOX regimen, Irinotecan - Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 88 | 2025-11-20 | 2026-04-28 |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer Drug: Ivonescimab Injection, Drug: Bevacizumab Injection - Metastatic Colorectal Cancer (CRC) | Phase 3 | Recruiting | Summit Therapeutics | 600 | 2025-11-18 | 2026-10-06 |
| Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 28 | 2025-11-18 | 2026-06-26 |
| Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA Ivonescimab, 5-Fluorouracil, Oxaliplatin - Stomach Cancer Stage IV, Esophagus Cancer | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2025-10-10 | 2026-08-28 |
| Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients Ivonescimab, FOLFOX regimen - Biliary Tract Cancer | Phase 2 | Recruiting | UNICANCER | 72 | 2025-10-09 | 2026-08-28 |
| Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer Ivonescimab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 90 | 2025-07-28 | 2026-05-20 |
Showing 20 of 39. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Colorectal Neoplasms (5) · Clostridium Infections (4) · Muscular Dystrophy, Duchenne (3) · Carcinoma, Renal Cell (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma, Mucinous (1) · Adrenocortical Carcinoma (1) · Biliary Tract Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Diarrhea (1) · Endometrial Neoplasms (1)
Carboplatin (5) · Fluorouracil (4) · Leucovorin (4) · Oxaliplatin (4) · Pemetrexed (4) · pembrolizumab (4) · ridinilazole (4) · SMT C1100 (3) · Vancomycin (3) · Bevacizumab (2) · Biopsy (2) · Folfox protocol (2) · Irinotecan (2) · Magnetic Resonance Spectroscopy (2) · Paclitaxel (2)
United States (31) · France (10) · United Kingdom (8) · Canada (6) · Spain (6) · China (5) · Italy (5) · Germany (4) · Greece (4) · Poland (4) · Belgium (3) · Hungary (3) · Japan (3) · Mexico (3) · Czechia (2)
Lori Styles, MD (2) · Anuj D Patel, MD (1) · Aung Naing, MD (1) · Beth Helmink, MD (1) · David Malka, MD (1) · Franceso Muntoni, MD (1) · Helen Roper, MD (1) · Helena Yu, MD (1) · Imelda Hughes, MD (1) · Indu Lal (1) · Ivan Borbath, MD (1) · Jessics J Lin, MD (1) · John Bridgewater, MD (1) · Jonathan W Goldman (1)
PMID 27055247, PMID 28461207, PMID 29718329, PMID 30767587, PMID 38305378, PMID 42636833, PMID 42669571
2025 (3), 2015 (1)